Multicenter Prospective Randomized Study of MaioRegenTM Prime vs. Debridement (Surgical Standard of Care (SSOC)) for the Treatment of Osteochondral Lesion of the Knee Joint OSTEOCONFIRM study Studio prospettico multicentrico randomizzato di MaioRegen....

Title

Code

OSTEOCONFIRM

Type

Indagine clinica con Dispositivo Medico

Start Year

2026

Status

In Corso

Principal Investigator

051-6366111 (centralino)

stefano.zaffagnini@unibo.it

Zaffagnini Stefano, MD

Director

2nd Orthopaedic and Traumatologic Clinic

Operational unit that carry out the study

complex unit

Clinica Ortopedica e Traumatologica II

Director

Zaffagnini Stefano, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. OSTEOCONFIRM

Friday 17 July 2026, 15:59

PG0008680_2026_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

Sito Web Istituto Ortopedico Rizzoli

DIPARTIMENTO RIZZOLI-SICILIA

Multicenter Prospective Randomized Study of MaioRegenTM Prime vs. Debridement (Surgical Standard of Care (SSOC)) for the Treatment of Osteochondral Lesion of the Knee Joint OSTEOCONFIRM study Studio prospettico multicentrico randomizzato di MaioRegen....

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in